Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Cureus ; 16(2): e55027, 2024 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-38550423

RESUMO

BACKGROUND: Smoking is a well-known risk factor for various health problems, including oral cancer. P16 and P53 proteins are involved in cell cycle regulation and proliferation, and their expression levels can provide insights into cellular health. OBJECTIVE: This study aims to evaluate the cellular changes and immunohistochemistry expression of p53 and p16 in the oral mucosa among Saudi smokers. METHOD: In a cross-sectional study obtained by scraping the buccal mucosa, 1000 samples were collected from 2022 to 2023. All of the study's participants were Saudi citizens of both genders. Seven hundred cigarette smokers and 300 nonsmokers made up the controls, using two sampling techniques: initially purposive and then snowball sampling. The materials were subjected to immunohistochemical analysis for P16 and P53 protein overexpression. The samples were scored based on the percentage of positively stained cells and staining intensity. The data were analyzed using SPSS, and categorical variables were identified as frequencies and percentages using the chi-squared test; a value of (P<0.05) was considered significant. RESULT: Cigarette smokers demonstrate significantly higher rates of cytological inflammation, reverse cytological infection, atypia, and binucleated/multinucleated cells compared to nonsmokers, with an overall abnormal result rate of 46% versus 18.7%, respectively (P=0.024). The study found higher P53 and P16 expression among smokers (7.14% and 2.14%, respectively) compared to nonsmokers (0.1% and 0.33%) (P=0.038). No significant differences were observed in P53/P16 expression across age groups (P=0.72) or between male and female participants (P=0.25). CONCLUSION: These findings highlight the detrimental effects of smoking on cellular health and reinforce the importance of smoking cessation in reducing the risk of developing cytological abnormalities and associated diseases. These results highlight the association of smoking with increased biomarker expression, emphasizing its relevance in understanding oral health risks.

2.
Med Oncol ; 41(1): 38, 2023 Dec 29.
Artigo em Inglês | MEDLINE | ID: mdl-38157146

RESUMO

The glutamine synthetase (GS) facilitates cancer cell growth by catalyzing de novo glutamine synthesis. This enzyme removes ammonia waste from the liver following the urea cycle. Since cancer development is associated with dysregulated urea cycles, there has been no investigation of GS's role in ammonia clearance. Here, we demonstrate that, although GS expression is increased in the setting of ß-catenin oncogenic activation, it is insufficient to clear the ammonia waste burden due to the dysregulated urea cycle and may thus be unable to prevent cancer formation. In vivo study, a total of 165 male Swiss albino mice allocated in 11 groups were used, and liver cancer was induced by p-DAB. The activity of GS was evaluated along with the relative expression of mTOR, ß-catenin, MMP-14, and GS genes in liver samples and HepG2 cells using qRT-PCR. Moreover, the cytotoxicity of the NH3 scavenger phenyl acetate (PA) and/or GS-inhibitor L-methionine sulfoximine (MSO) and the migratory potential of cells was assessed by MTT and wound healing assays, respectively. The Swiss target prediction algorithm was used to screen the mentioned compounds for probable targets. The treatment of the HepG2 cell line with PA plus MSO demonstrated strong cytotoxicity. The post-scratch remaining wound area (%) in the untreated HepG2 cells was 2.0%. In contrast, the remaining wound area (%) in the cells treated with PA, MSO, and PA + MSO for 48 h was 61.1, 55.8, and 78.5%, respectively. The combination of the two drugs had the greatest effect, resulting in the greatest decrease in the GS activity, ß-catenin, and mTOR expression. MSO and PA are both capable of suppressing mTOR, a key player in the development of HCC, and MMP-14, a key player in the development of HCC. PA inhibited the MMP-14 enzyme more effectively than MSO, implying that PA might be a better way to target HCC as it inhibited MMP-14 more effectively than MSO. A large number of abnormal hepatocytes (5%) were found to be present in the HCC mice compared to mice in the control group as determined by the histopathological lesions scores. In contrast, PA, MSO, and PA + MSO showed a significant reduction in the hepatic lesions score either when protecting the liver or when treating the liver. The molecular docking study indicated that PA and MSO form a three-dimensional structure with NF-κB and COX-II, blocking their ability to promote cancer and cause gene mutations. PA and MSO could be used to manipulate GS activities to modulate ammonia levels, thus providing a potential treatment for ammonia homeostasis.


Assuntos
Carcinoma Hepatocelular , Neoplasias Hepáticas , Masculino , Camundongos , Animais , Neoplasias Hepáticas/patologia , Carcinoma Hepatocelular/patologia , beta Catenina/metabolismo , Glutamato-Amônia Ligase/genética , Glutamato-Amônia Ligase/metabolismo , Amônia/metabolismo , Amônia/uso terapêutico , Nitrogênio/uso terapêutico , Metaloproteinase 14 da Matriz , Simulação de Acoplamento Molecular , Serina-Treonina Quinases TOR , Homeostase , Ureia/uso terapêutico
3.
Ann Saudi Med ; 35(3): 222-30, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26409797

RESUMO

BACKGROUND AND OBJECTIVES: The prevalence of gestational diabetes (GDM) has increased recently worldwide, mainly due to adoption of the International Association of Diabetes and Pregnancy Study Group (IADPSG) criteria. The objectives of this study were to determine the prevalence of GDM in Saudi women and to assess risk factors and pregnancy outcomes using the IADPSG criteria. DESIGN AND SETTING: A prospective descriptive study of pregnant Saudi women presenting at the Maternity and Children Hospital, Medina, Saudi Arabia, between October 2011 and June 2014. METHODS: Fasting plasma glucose, glycated hemoglobin, and random plasma glucose concentrations were obtained for all participants at the first antenatal visit. In women with normal results, screening for GDM was performed at 24 to 28 weeks of gestation, with a 75-g oral glucose tolerance test (OGTT). Women who had GDM were treated with diet, exercise, and insulin as needed. Pregnancy outcomes were recorded after delivery. Multiple logistic regression was used to assess possible risk factors for GDM. RESULTS: Early screenings showed abnormal glucose in 211 of 954 women (22.1%). In 445 women, the OGTT showed GDM in 183 women (39.4%). GDM cases identified by OGTT and by early screening increased the rate of GDM to 51% (292 women). Older maternal age, higher body mass index, higher blood pressure, past GDM, history of delivering a malformed child, and family history of diabetes were the main risk factors for GDM. GDM increased the risk of neonatal hypoglycemia (OR 9.353), low Apgar score (OR 5.546), and induction of labor (OR 2.33). The newborns of GDM mothers had a higher birth weight: 3043 g vs. 2890 g in the non-GDM group (P=.004). Other maternal and neonatal outcomes were not significantly different between the two groups. CONCLUSION: The prevalence of GDM is high among Saudi women. Timely and effective treatment reduces perinatal morbidity and improves outcomes.


Assuntos
Diabetes Gestacional/epidemiologia , Resultado da Gravidez , Adolescente , Adulto , Peso ao Nascer , Glicemia/análise , Pressão Sanguínea , Índice de Massa Corporal , Diabetes Gestacional/etiologia , Diabetes Gestacional/terapia , Jejum/sangue , Feminino , Teste de Tolerância a Glucose , Hemoglobinas Glicadas/análise , Humanos , Hipoglicemia/epidemiologia , Hipoglicemia/etiologia , Recém-Nascido , Doenças do Recém-Nascido/epidemiologia , Doenças do Recém-Nascido/etiologia , Modelos Logísticos , Idade Materna , Pessoa de Meia-Idade , Gravidez , Cuidado Pré-Natal , Prevalência , Estudos Prospectivos , Fatores de Risco , Arábia Saudita/epidemiologia , Adulto Jovem
4.
Saudi Med J ; 33(5): 500-7, 2012 May.
Artigo em Inglês | MEDLINE | ID: mdl-22588810

RESUMO

OBJECTIVE: To investigate intestinal motility changes due to uremia, and the effect of pretreatment with erythropoietin. METHODS: This randomized control study was conducted in the Department of Physiology, Faculty of Medicine, Ain Shams University, Cairo, Egypt from September 2010 to July 2011. Forty adult female Wistar albino rats were allocated into 3 groups: control group, gentamicin-treated group, receiving intraperitoneal gentamicin sulphate (100 mg/kg for 5 days), and erythropoietin-gentamicin-treated group, receiving subcutaneous erythropoietin (1000 IU/kg for 3 days) prior to gentamicin injection. Isolated segments of duodenum and descending colon was subjected to in vitro motility study. Plasma creatinine and urea were assayed. RESULTS: Induction of acute renal failure by gentamicin treatment resulted in a significant decrease in frequency of contraction of the duodenum and descending colon, an increase in the average duration of contraction of the duodenum, and a significant decrease in the average force of contraction in the descending colon. Moreover, the average force of contraction in response to acetylcholine was significantly decreased in the duodenum. The erythropoietin-gentamicin-treated group revealed a significant decrease in plasma creatinine and urea, and a significant increase in the duodenal average force of contraction and motility index, and colonic frequency. The duodenal absolute and average forces of contraction after acetylcholine increased significantly. CONCLUSION: Acute uremia impairs small and large intestinal motility, probably due to uremic toxins and autonomic dysfunction. Erythropoietin pretreatment protected against intestinal dysmotility through the improvement of renal function and its neurotropic action.


Assuntos
Eritropoetina/administração & dosagem , Motilidade Gastrointestinal/efeitos dos fármacos , Uremia/tratamento farmacológico , Doença Aguda , Animais , Colo/efeitos dos fármacos , Colo/fisiopatologia , Creatinina/sangue , Modelos Animais de Doenças , Duodeno/efeitos dos fármacos , Duodeno/fisiopatologia , Feminino , Gentamicinas/farmacologia , Distribuição Aleatória , Ratos , Ratos Wistar , Valores de Referência , Sensibilidade e Especificidade , Uremia/induzido quimicamente , Uremia/fisiopatologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA